U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07311993) titled 'Phase 1 Parallel Study of CLR 125 in Triple Negative Breast Cancer' on Nov. 13, 2025.
Brief Summary: The goal of this clinical trial is to evaluate the safety and efficacy of 3 different dose levels of CLR 125 in patients with advanced triple negative breast cancer. The main questions the study aims to answer are:
* What dose and regimen should be used in future trials of CLR 125 in patients with advanced triple negative breast cancer.
* What side effects do participants have when taking CLR 125.
Participants will:
* Have CLR 125 administered via infusion 4 times each cycle; repeated every 8 weeks.
* Visit the clinic once every ...